Turkey Oncology Therapeutics Market Analysis

Turkey Oncology Therapeutics Market Analysis


$ 3999

By 2030, it is anticipated that the Turkey Oncology Therapeutics Market will reach a value of $2.8 Bn from $1.5 Bn in 2022, growing at a CAGR of 8.9% during 2022-30. The Oncology Therapeutics Market in Turkey is dominated by a few domestic pharmaceutical companies such as Deva Holding, Mustafa Nevzat, and Abdi İbrahim. The Oncology Therapeutics Market in Turkey is segmented into different types of cancer and different therapy types. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for Turkey Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.

ID: IN10TRPH042 CATEGORY: Pharmaceuticals GEOGRAPHY: Turkey AUTHOR: Dr. Vishwa Modhia

Buy Now

Turkey Oncology Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Turkey Oncology Therapeutics Market will reach a value of $2.8 Bn from $1.5 Bn in 2022, growing at a CAGR of 8.9% during 2022-30.

Turkey is an upper middle-income, developing transcontinental country located in Southeastern Europe and Southwestern Asia bordering the Black Sea. In Turkey, public hospitals, hospitals linked with medical colleges, and private hospitals provide health care. Acibadem is a well-known name in the Turkish medical industry. According to the most recent WHO data, the number of new cancer cases in Turkey in 2020 was 2,33,834. On behalf of the Ministry of Health, the cancer registry conducts epidemiological studies and develops Turkey's cancer control policies and national programmes.

Turkey has one of the world's most recognised social security systems, with free healthcare and access to a wide range of cutting-edge cancer medicines. Turkey's government spent 4.6% of its GDP on healthcare in 2020.

Turkey Oncology Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers Analysis

The Ministry of Health has created a National Cancer Control Program with the goal of preventing cancer, detecting it early, providing high-quality treatment, and improving cancer patients' quality of life. The Turkish Ministry of Health is concerned with all of the country's major diseases and health issues, not just cancer. Currently, 14 Turkish cities, comprising 50.2% of the population, have population-based cancer registry facilities. Medicine prices in Turkey are consistently cheaper than those in several African nations. In Turkey, radiation oncology is an essential component of the multidisciplinary therapy approach. By December 2021, there will be 593 active radiation oncologists. Turkey has become a popular medical tourism destination, with an increasing number of patients seeking high-quality, low-cost oncology care. These aspects could boost Turkey's Oncology Therapeutics Market.

Market restraints

In Turkey, the average cost of oncology operations is $65250. The treatment's high prices can have an impact on its affordability and accessibility among patients. Diagnostic and therapeutic facilities are not evenly distributed throughout the country, and it is critical to make contemporary diagnostic and therapeutic facilities more accessible in rural areas. These factors may deter new entrants into the Turkey Oncology Therapeutics Market.

Competitive Landscape

Key Players

  • Abdi İbrahim: Abdi İbrahim is one of the leading pharmaceutical companies in Turkey, with a strong presence in the oncology market. The company offers a wide range of oncology products, including chemotherapy drugs, immunotherapy drugs, and targeted therapy drugs
  • Mustafa Nevzat: Mustafa Nevzat is another major player in Turkey's oncology therapeutics market. The company offers a variety of oncology drugs, including chemotherapy drugs, immunotherapy drugs, and supportive care drugs
  • Nobel İlaç: Nobel İlaç is a Turkish pharmaceutical company that specializes in oncology, haematology, and supportive care drugs. The company's oncology portfolio includes chemotherapy drugs, targeted therapy drugs, and supportive care drugs
  • Eczacıbaşı-Monrol: Eczacıbaşı-Monrol is a joint venture between Eczacıbaşı, one of Turkey's leading conglomerates, and the French pharmaceutical company Sanofi. The company offers a range of oncology products, including chemotherapy drugs, targeted therapy drugs, and supportive care drugs
  • Deva Holding: Deva Holding is another major player in Turkey's oncology therapeutics market. The company's oncology portfolio includes chemotherapy drugs, immunotherapy drugs, and supportive care drugs

Healthcare Policies and Reimbursement Scenarios

The Turkish Medicines and Medical Devices Agency (TITCK) is the regulatory authority in Turkey in charge of authorising and regulating therapeutic medications. The Turkish Government's Social Security Institution (SSI) reimburses 86 % of the population in the Turkish healthcare system. In 2019, private insurance companies supported 2.9% of the “Health Expenditure Budget of Turkey. The MoH is responsible for licensing drugs in Turkey.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Therapeutics Segmentation

By Application (Revenue, USD Billion):

  • Blood Cancer
  • ?Colorectal Cancer
  • Gastrointestinal Cancer
  • Gynaecologic Cancer
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • ?Others

By Drugs (Revenue, USD Billion):

  • Revlimid
  • Avastin
  • Herceptin
  • Rituxan
  • Opdivo
  • Gleevec
  • Velcade
  • Imbruvica
  • Ibrance
  • Zytiga
  • Alimta
  • Xtandi
  • Tarceva
  • Perjeta
  • Temodar
  • Others

By Therapy (Revenue, USD Billion):

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hormonal Therapy
  • Others

By Route of Administration (Revenue, USD Billion):

  • Oral
  • Parenteral
  • Others

By Distribution Channel (Revenue, USD Billion):

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • ?Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.

By 2030, it is anticipated that the Turkey Oncology Therapeutics market will reach a value of $2.8 Bn from $1.5 Bn in 2022, growing at a CAGR of 8.9% during 2022-2030.

In Turkey, the regulatory authority responsible for approving and regulating therapeutic drugs is the Turkish Medicines and Medical Devices Agency (TITCK).

The Oncology Therapeutics Market in Turkey is dominated by a few domestic pharmaceutical companies such as Deva Holding, Mustafa Nevzat, and Abdi İbrahim.


Last updated on: 25 October 2023
Updated by: Anish Swaminathan

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up